EMEA-003217-PIP01-22
Key facts
| Active substance |
Modakafusp Alfa
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0282/2022
|
| PIP number |
EMEA-003217-PIP01-22
|
| Pharmaceutical form(s) |
All pharmaceutical forms
|
| Condition(s) / indication(s) |
Treatment of multiple myeloma
|
| Route(s) of administration |
All routes of administration
|
| Contact for public enquiries |
Takeda Pharma A/S
Tel. +44 (0)3333000181 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|